Ralimetinib is a selective inhibitor that blocks phosphorylation of MK2 at Thr334, without affecting the phosphorylation of p38alpha MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib functions as an ATP-competitive inhibitor of p38 MAPK alpha/beta, demonstrating IC50 values of 5.3 and 3.2 nM, respectively, and is under investigation as an anti-inflammatory and anticancer therapeutic.
Molekulargewicht:
420.53
Reinheit:
99.21%
CAS Nummer:
[862505-00-8]
Formel:
C24H29FN6
Target-Kategorie:
Others|||MAPK|||p38 MAPK|||Autophagy
T16721
T16721
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
